In addition, some of studies included in this review had short follow-up periods which limits understanding of long-term efficacy and safety of NO-sGC-cGMP pathway-targeting agents for the management of PH due to COPD. This evidence concerns the gene SGCB and chronic obstructive pulmonary disease.